Many cancer subsets, including acute myeloid leukemia (AML), do not have strong identifiable markers. Scientists are still investigating novel biomarkers to improve immunotherapy, including CAR T cell ...

The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to ...

“Approximately 46,000 people are diagnosed with AML, ALL, and MDS in the US each ... Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, said in a statement.

SLS009 is associated with an improvement in survival among patients with relapsed/refractory acute myeloid leukemia.

Chris Ehrlich, CEO of CERo Therapeutics Inc. (Nasdaq: CERO), a leading immunotherapy company ... to enter the clinic in patients with Acute Myeloid Leukemia and Ovarian and Non-Small Cell Lung ...

March 27, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company ... measurable residual disease positive acute myeloid ...

Cancer immunotherapy is a therapy used to treat ... receptor (CAR)-engineered cell therapies for acute myeloid leukemia (AML) is the absence of highly specific tumor antigens.

and to providing progress updates on our AML program in the near term.” About CERo Therapeutics Holdings, Inc. CERo is an innovative immunotherapy company advancing the development of next ...

March 27, 2025 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc., (Nasdaq: CERO) (“CERo” or the “Company”) an innovative immunotherapy company seeking to advance the next generation of ...